Palivizumab use in preterm neonates

Irish Medical Journal

Volumn 103, Issue 5, 2010, Pages

  Kingston, S ^a   Murphy, B P ^a  

^a Irish Centre for Fetal and Neonatal Translational Research   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BUDGET; CHRONIC LUNG DISEASE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; HOSPITAL ADMISSION; HUMAN; IMMUNOPROPHYLAXIS; IRELAND; MATERNITY WARD; MEDICAL SPECIALIST; NEWBORN; PEDIATRICIAN; PRACTICE GUIDELINE; PREMATURITY; QUESTIONNAIRE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRAL BRONCHIOLITIS; BRONCHIOLITIS; CLINICAL PRACTICE; FEMALE; MALE; STATISTICS; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; CLINICAL PROTOCOLS; FEMALE; GUIDELINE ADHERENCE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; IRELAND; MALE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 77954411626     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956;92:544-549
2. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 1957:66:281-290.
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high risk infants. Paediatrics 1998;102:531-7
4. Feltes TM, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40.
5. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 2003; 22:S46-54.
6. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003; 22:823-7.
7. Vogel AM, McKinlay MJ, Ashton T, et al. Cost effectiveness of palivizumab in New Zealand. J Paediatr Child Health. 2002; 38:352-357.
8. Carole A Reeve, John S Whitehall, Petra G Buettner, Robert Norton, David M Reeve, Fleur Francis. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006; 42:253-258.
9. Nuijten MJ, Wittenberg W, Lebmeier M. Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis. Original Research Article Pharmacoeconomics. 25:55-71, 2007.
10. Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and Management of Bronchiolitis. Pediatrics 2006 118: 1774-1793
11. Joint Committee on Immunisation and Vaccination. Meeting minutes, 22 June 2005. London, UK. (http://www.advisorybodies.doh.gov.uk/JCVI/mins220605.htm)
12. Cahill P, Finan E, Loftus BG. Management of bronchiolitis: current practices in Ireland. Ir Med J. 2002 Jun; 95:167-9
13. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, M Harrington, Boron M. Prevention of hospitalisation due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J. Perinat 2008; 28:511-517
14. Goddard N.L, Cooke M.C, Gupta R.K, Nguyen-Van-Tam J.S. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. Epidemiol. Infect. 2007; 135:159-162
15. Manzoni P, Sala U, Gomirato G, Coscia A, Fabris C. Optimal timing and dosing intervals of palivizumab in premature neonates: Still some work to do. Pediatrics 2005; 115:1439-1440
16. Wang D, Cummins C, Bayliss S, Sandercock J, Buris A. Immunoprophylaxis against respiratory virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Tech Assess 2008; Vol.12:No.36
17. http://www.esri.ie/health_information/nprs/nprs_reports/ Accessed Sept 2009